Macau Casino Gambli...
Health Care: Drugs
Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ)
$10.09 -0.15 | -1.46%
06/01/12 - 04:00 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 70.23M | 74.60M | 137.47M | 191.79M |
| Receivables | 1.47M | 14.12M | 6.04M | 4.19M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 152.03M | 254.14M | 293.53M | 442.25M |
| Property, Plant & Equipment, Gross | 45.57M | 44.63M | 39.90M | 34.95M |
| Accumulated Depreciation & Depletion | 30.92M | 26.34M | 21.58M | 15.76M |
| Property, Plant & Equipment, Net | 14.64M | 18.29M | 18.32M | 19.19M |
| Intangibles | 275.00K | 448.00K | 622.00K | 795.00K |
| Other Non-Current Assets | 114.97M | 120.39M | 160.35M | 87.06M |
| Total Non-Current Assets | 129.89M | 139.13M | 187.85M | 112.43M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 281.92M | 393.26M | 481.38M | 554.68M |
| Accounts Payable | 5.80M | 9.31M | 12.49M | 2.59M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 484.00K | 0.00 | 6.48M | 7.67M |
| Total Current Liabilities | 80.99M | 102.05M | 110.73M | 99.45M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 3.73M | 2.87M | 2.61M | 2.73M |
| Other Non-Current Liabilities | 79.20M | 130.12M | 190.08M | 250.37M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 82.93M | 132.99M | 192.69M | 253.10M |
| Total Liabilities | 163.92M | 235.03M | 303.42M | 352.55M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 118.00M | 158.23M | 177.96M | 202.12M |
| Common Par | 427.00K | 423.00K | 0.00 | 0.00 |
| Additional Paid In Capital | 518.73M | 500.44M | 476.66M | 452.77M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -401.00M | -343.35M | -299.83M | -252.24M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -165.00K | 714.00K | 1.13M | 1.60M |
| Total Capitalization | 118.00M | 158.23M | 177.96M | 202.12M |
| Total Equity | 118.00M | 158.23M | 177.96M | 202.12M |
| Total Liabilities & Stock Equity | 281.92M | 393.26M | 481.38M | 554.68M |
| Total Common Shares Outstanding | 42.72M | 42.34M | 41.84M | 41.42M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 42.41M | 42.04M | 41.63M | 41.08M |
| Diluted Weighted Shares Outstanding | 42.41M | 42.04M | 41.63M | 41.08M |
| Number of Employees | 116 | 172 | 178 | 170 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ALNY
- Portfolio NameUser Type
- UserThe #1 Growth Fund To Make ...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Userkite
- UserPART 6 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
- ContributorHealthcare Short Squeezes f...
- UserS.A.Chili
- UserHancock Hallock Firm
Latest ALNY Headlines from TheStreet
- 5 Stocks Insiders Love Right Now 02.24.12 | 12:02 pm
- 8 Stocks Rising on Huge Volume 02.15.12 | 02:02 pm
- 'Mad Money Lightning Round': Stay Long Sandridge 01.03.12 | 07:01 pm
- Cramer's 'Mad Money' Recap: Betting Against the Bears (Update 2) 01.03.12 | 06:01 pm
- AK Steel, Applied Materials: New Ratings 02.23.11 | 09:02 am
- Layoffs Mount in 2010: What Does It Mean for 2011? 01.06.11 | 05:01 pm
- Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results  Earnings Call Transcript 11.03.10 | 10:11 pm
- Biotech Stock Mailbag: Cyclacel Pharma 10.08.10 | 07:10 am
- Alnylam Cuts Jobs On Partner Exit 09.24.10 | 07:09 am
- Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript 08.05.10 | 12:08 am
Press Releases for ALNY
- Alnylam Announces Top-Line Results Of Phase IIb Clinical Trial Of ALN-RSV01, An Inhaled RNAi Therapeutic For The Treatment Of Respiratory Syncytial Virus (RSV) Infection - Business Wire 05.30.12 | 06:05 am
- Alnylam And PBL Sign License Agreement For Baulcombe & Hamilton RNAi Patent - Business Wire 05.23.12 | 08:05 am
- Alnylam Pharmaceuticals Reports First Quarter 2012 Financial Results - Business Wire 05.03.12 | 04:05 pm
- Alnylam To Webcast Conference Call Discussing First Quarter 2012 Financial Results - Business Wire 04.26.12 | 04:04 pm
- Alnylam To Webcast Presentation At Future Leaders In The Biotech Industry Conference - Business Wire 04.13.12 | 04:04 pm
- Alnylam To Webcast Presentation At 11th Annual Needham Healthcare Conference - Business Wire 03.27.12 | 04:03 pm
- Alnylam Initiates Phase I Clinical Study Of ALN-TTR02, An RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR-Mediated Amyloidosis (ATTR) - Business Wire 03.19.12 | 08:03 am
- Alnylam Retains Key Claims For Kinesin Spindle Protein (KSP) RNAi Patent In Interference Proceedings - Business Wire 03.14.12 | 06:03 am
- Alnylam To Webcast Presentation At Barclays Capital Global Healthcare Conference - Business Wire 03.06.12 | 04:03 pm
- Alnylam And The University Of Massachusetts Medical School Announce Tuschl I Patent Upheld In European Opposition Proceedings - Business Wire 03.01.12 | 11:03 am
Partner Headlines for ALNY
- The Zacks Analyst Blog Highlights: Amgen, Sanofi, Regeneron, Alnylam and Coach - Press Releases - Zacks 03.28.12 | 09:03 am
- What Alnylam Doesn't Want You To Know - Seeking Alpha 03.16.12 | 09:03 am
- Tekmira: RNAi Company With Long Term Potential, Short Term Catalysts - Seeking Alpha 03.07.12 | 08:03 am
- Company News for February 15, 2012 - Corporate Summary - Zacks 02.15.12 | 10:02 am
- Alnylam Pharma Up 8% After Pricing Public Offering - Benzinga 02.15.12 | 09:02 am
- Alnylam Delivers In-Line Numbers - Analyst Blog - Zacks 02.13.12 | 10:02 am
- Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach - Seeking Alpha 01.30.12 | 09:01 am
- Alnylam Down to Neutral - Analyst Blog - Zacks 01.20.12 | 04:01 pm
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- Alnylam States Preclinical Data - Analyst Blog - Zacks 12.30.11 | 04:12 pm
